HOLLISTON, Mass. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announces its strategic action plan and financial targets for rest of year 2019 through 2021. Key strategic actions and financial targets to position Harvard Bioscience for long-term profitable

HOLLISTON, Mass. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that its Board of Directors has elected Alan Edrick to Harvard Bioscience’s Board of Directors, effective September 3, 2019 . Bertrand Loy , Lead Independent Director, said “After

HOLLISTON, Mass. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced that Chairman, President and CEO, Jim Green , will be presenting at the Janney Montgomery Scott Healthcare Conference in New York City on September 9, 2019 at 9:05 a.m. EDT .

- GAAP and adjusted non-GAAP revenue of $29.6 million - GAAP and adjusted non-GAAP earnings per share of $(0.01) and $0.04 , respectively - 2019 guidance remains unchanged HOLLISTON, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), today announced

HOLLISTON, Mass. , July 19, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that in connection with Michael Rossi being named Chief Financial Officer on July 18, 2019 , the Compensation Committee of the Board of Directors approved the grant of equity awards to Mr.

HOLLISTON, Mass. , July 19, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience , Inc. (Nasdaq: HBIO) will announce its quarterly results for the second quarter ended June 30, 2019 after market close on July 25, 2019 and hold a conference call to discuss the results for the second quarter on July 25, 2019

HOLLISTON, Mass. , July 18, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Michael Rossi has been named Chief Financial Officer, effective immediately.  Rossi most recently served as Chief Financial Officer of Laborie Medical Technologies , a global medical

HOLLISTON, Mass. , July 08, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that James Green has been named President and Chief Executive Officer of the Company by its Board of Directors, effective immediately. Additionally, Harvard Bioscience’s Board has appointed

Designed to Acquire and Synchronize Pre-clinical Signals from Disparate Sources ST. PAUL, Minn. and HOLLISTON, Mass. , June 26, 2019 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq: HBIO) and the global leader in wireless physiologic

Digital Telemetry Implant Saves Researchers Time and Money by Collecting More Data From One Implant ST. PAUL, Minn. and HOLLISTON, Mass. , May 15, 2019 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq: HBIO) and the global leader in wireless